Prospective, Randomized, Single-blind, Active-controlled (Part B), Multi-center Phase II Clinical Trial to Explore the Fixed Starting Dose and Treatment Schedule and to Evaluate the Safety of GX-E2 Administered Intravenously/Subcutaneously in the Anemic Patients Diagnosed with Chronic Kidney Disease Receiving Hemodialysis (HD)/Peritoneal dialysis (PD)

Trial Profile

Prospective, Randomized, Single-blind, Active-controlled (Part B), Multi-center Phase II Clinical Trial to Explore the Fixed Starting Dose and Treatment Schedule and to Evaluate the Safety of GX-E2 Administered Intravenously/Subcutaneously in the Anemic Patients Diagnosed with Chronic Kidney Disease Receiving Hemodialysis (HD)/Peritoneal dialysis (PD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs GX E2 (Primary) ; GX E2 (Primary) ; Darbepoetin alfa; Darbepoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Genexine
  • Most Recent Events

    • 25 Apr 2017 Planned number of patients changed from 250 to 252.
    • 25 Apr 2017 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top